Melinta Therapeutics Announces U.S. FDA Approval of Supplemental New Drug Application for BAXDELA® (delafloxacin) for the Treatment of Community-Acquired Bacterial Pneumonia (CABP)

Matthew Durham
Omnidynamic Marketing

Suma Ramadas, PhD
Medical Affairs

Joey Cohen
Medication Adherence

Stacey Gandler
Brand Nourishment

David Linetsky
Point-of-Care Marketing

Liz Kane
Impactful Strategy

Amy Giles
Increasing Engagement

Matt Turner
Patient Affordability

Daniel Sontupe
Market Access

Brenda Snow
Authentic Patient Voice

Bud Bilanich
Success Coach

Paul Theisen
Patient Acquisition

Pat Purcell
Meeting Engagement

Frank Burrell
Scientific Storytelling